Novartis Leads MNC Generics Foray In China
This article was originally published in PharmAsia News
Executive Summary
Most major pharmaceutical corporations allocate little or no resources to generic drug development. Novartis is bucking the trend with its pioneering efforts in this area. The company sees great opportunities in generics: mounting difficulties in approval of new drugs are leading to a global decline in patented drug development and production, while governments worldwide are increasing the proportion of generic drugs in their medical insurance coverage. In China, 70 percent of the pharmaceutical market is dominated by generic drugs, most of which are produced by local enterprises. Novartis China acknowledges the challenges of higher production costs and will focus on the strategy of brandname, quality and services to gain recognition. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.